Literature DB >> 2617955

New approach to eliminate HLA class I antigens from platelet surface without cell damage: acid treatment at pH 3.0.

Y Kurata1, M Oshida, H Take, T Furubayashi, H Nakao, Y Tomiyama, Y Kanayama, N Nagao, Y Okubo, T Yonezawa.   

Abstract

A new method was studied for eliminating HLA class I antigens from the surface of platelets without damaging the cells. Platelets were exposed to an acid solution (pH 3.0) to eliminate the antigenicity of HLA class I antigens. The reduction in antigenicities of HLA class I common antigen and individual HLA class I antigens by acid treatment was marked. Patients' sera which contained multispecific HLA antibodies reacted with PBS-treated platelets, but not with acid-treated platelets. No changes were observed in the antigenicities of glycoprotein Ib or glycoprotein IIb/IIIa. The viability of acid-treated platelets was 83%. Ultrastructural investigations revealed no significant difference between the PBS-treated platelets and acid-treated platelets. The platelet function studies showed that the aggregation of acid-treated platelets induced by various agonists was only slightly reduced compared with PBS-treated platelets. We propose that acid-treated platelets are promising for clinical use in patients refractory to platelet transfusions and may be superior to chloroquine-treated platelets for analysis of the specificity of antiplatelet antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2617955     DOI: 10.1111/j.1423-0410.1989.tb00823.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

Review 1.  Evaluation and management of platelet transfusion refractoriness.

Authors:  Hee-Jeong Youk; Sang-Hyun Hwang; Heung-Bum Oh; Dae-Hyun Ko
Journal:  Blood Res       Date:  2022-04-30

2.  Commentary: An enzymatic pathway in the human gut microbiome that converts A to universal O type blood.

Authors:  Oloche Owoicho; Charles Ochieng' Olwal; Osbourne Quaye
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.